长按二维码,关注官方公众号
You can share it to WeChat via the Qr code.
Join us for an enlightening webinar that delves into the cutting-edge strategies in PROTACs, a revolutionary approach to drug discovery that targets and degrades disease-causing proteins. Hear from leading experts as they unveil their insights into Linkerology, case studies in PROTAC development, and structure-guided optimization strategies. This event is a must-attend for scientists, researchers, and drug developers seeking to harness the power of PROTACs for the next generation of therapeutics.
Opening
Not Just Another Linker: Viva’s Approach to PROTAC Linkerology
Repurposing A Known Binder into Potent Heterobifunctional Degraders with Excellent in Vitro Metabolism: A BRD4 Case Study
Leveraging Structure and Biophysics in Rational PROTAC Optimization
Q&A Session
Opening
Not Just Another Linker: Viva’s Approach to PROTAC Linkerology
As part of our Global Team of Program Managers, David is based in Montreal, Canada, and oversees a portfolio of North American and European Clients. He also works along Dr. Garnier on the development of VIVA's Chemistry-enabling Platforms like the PROTAC Libraries. David is a seasoned Drug Hunter from his career at Sygnature Discovery (UK), where he led or contributed to multidisciplinary research, including the discovery of Inobrodib, a first-in-class oral dual bromodomain inhibitor drug against multiple specific cancer types, and several Kinase Inhibitors as inhaled candidates for the treatment of COPD and Asthma.
Repurposing A Known Binder into Potent Heterobifunctional Degraders with Excellent in Vitro Metabolism: A BRD4 Case Study
Jean-Marc is a highly experienced program manager, having worked from target validation with tool compound up to pre-clinical candidate selection. Since 2016, he has been leading the medicinal chemistry of a first-in-class necroptosis inhibitor program from fragment-based drug discovery (FBDD) to pre-clinical candidate selection (PCCs). Jean-Marc is named as an inventor in over 10 granted patents, some of which related to bifunctional degraders.
Jean-Marc obtained his PhD in organic chemistry from the University of Paris-Sud Orsay (France). He then took up a postdoctoral position in organocatalysis at Macquarie University in Sydney before working as a senior scientist at Pfizer-SRG and later at Peakdale Chemistry Services in Sandwich, UK. And before joining SYNthesis in 2016, Jean-Marc worked as a medicinal chemist at the Walter and Eliza Hall Institute of Medical Research in Parkville, focusing on the development of epigenetic inhibitors.
Leveraging Structure and Biophysics in Rational PROTAC Optimization
Dr. Michael Roy is a leading medicinal chemist/structural biologist with expertise in targeted protein degradation, currently based at WEHI in Melbourne. His research focuses on employing small molecule, chemical biology, and structural approaches to study and target druggable nodes in cancer signaling pathways. During his postdoctoral research at the University of Dundee in the lab of Professor Alessio Ciulli, Michael made significant contributions to the development of ACBI1 and ACBI2, degraders targeting SMARCA2/4 subunits of the BAF chromatin remodeling complex. Most recently, as a Project Director for an international PROTAC collaboration between WEHI and global pharmaceutical company Boehringer Ingelheim, Michael has co-led a team of talented medicinal chemists, structural biologists and cell biologists focused on development of PROTACs for oncology.
Q&A Session
As part of our Global Team of Program Managers, David is based in Montreal, Canada, and oversees a portfolio of North American and European Clients. He also works along Dr. Garnier on the development of VIVA's Chemistry-enabling Platforms like the PROTAC Libraries. David is a seasoned Drug Hunter from his career at Sygnature Discovery (UK), where he led or contributed to multidisciplinary research, including the discovery of Inobrodib, a first-in-class oral dual bromodomain inhibitor drug against multiple specific cancer types, and several Kinase Inhibitors as inhaled candidates for the treatment of COPD and Asthma.
Jean-Marc is a highly experienced program manager, having worked from target validation with tool compound up to pre-clinical candidate selection. Since 2016, he has been leading the medicinal chemistry of a first-in-class necroptosis inhibitor program from fragment-based drug discovery (FBDD) to pre-clinical candidate selection (PCCs). Jean-Marc is named as an inventor in over 10 granted patents, some of which related to bifunctional degraders.
Jean-Marc obtained his PhD in organic chemistry from the University of Paris-Sud Orsay (France). He then took up a postdoctoral position in organocatalysis at Macquarie University in Sydney before working as a senior scientist at Pfizer-SRG and later at Peakdale Chemistry Services in Sandwich, UK. And before joining SYNthesis in 2016, Jean-Marc worked as a medicinal chemist at the Walter and Eliza Hall Institute of Medical Research in Parkville, focusing on the development of epigenetic inhibitors.
Dr. Michael Roy is a leading medicinal chemist/structural biologist with expertise in targeted protein degradation, currently based at WEHI in Melbourne. His research focuses on employing small molecule, chemical biology, and structural approaches to study and target druggable nodes in cancer signaling pathways. During his postdoctoral research at the University of Dundee in the lab of Professor Alessio Ciulli, Michael made significant contributions to the development of ACBI1 and ACBI2, degraders targeting SMARCA2/4 subunits of the BAF chromatin remodeling complex. Most recently, as a Project Director for an international PROTAC collaboration between WEHI and global pharmaceutical company Boehringer Ingelheim, Michael has co-led a team of talented medicinal chemists, structural biologists and cell biologists focused on development of PROTACs for oncology.
